moderna®

Bivalent COVID Booster Ph 2/3 Interim Analysis (mRNA-1273.214)

June 8th, 2022

Forward-looking statements and Disclaimer

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's expectations regarding the endemic phase of COVID-19, including trends with respect to the risk of breakthrough hospitalization; Moderna's booster development strategy for the endemic phase of COVID-19; the ability of mRNA-1273.214 to trigger superior immunogenicity against the Omicron variant of the SARS-CoV-2 virus and to maintain non-inferior status against ancestral strains; the conduct of ongoing clinical trials for mRNA-1273.214; and the reactogenicity profile, safety and tolerability of mRNA-1273.214. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this presentation.

moderna

COVID booster development for endemic phase

Strategic rationale for seasonal booster	• Neutralizing titers (NT) will wane, similar to endemic HCoV • Decline in NT will increase risk of breakthrough hospitalization for those at higher risk (e.g., older adults, immune compromised) • Emergence of new variants of concern (VOC) could accelerate the impact of waning and broaden risk of breakthrough
Desired features for the northern hemisphere (NH) Fall/Winter '22-23 booster	• Improve durability of protective neutralizing antibodies against Omicron to 6+ months (i.e., the full NH fall-winter infection season) • Retain high and durable protection against prior VOC and ancestral strains • Broaden cross-protective immunity to increase potential for protection against a new (emergent) VOC mid-year

moderna

Overview Phase 2/3 (P205) study for mRNA-1273.214

All subject received mRNA-1273 primary series (100 µg) and mRNA-1273 booster (50 µg)

Trial	4th dose Booster	4th dose Dose	Subjects(n)	Comments
Phase 2/3 P205 *Only showing current arms*	**mRNA-1273**	50 µg	377	Enrolled February 21 to March 8
	.214 (32 Omicron mutations)	50 µg	437	Enrolled March 8 to March 23

mRNA-1273.214 also being evaluated in study in UK (P305) with ~1,500 participants per arm and mixed primary regimen

Arms enrolled sequentially, safety follow-up of 57 days for mRNA-1273 and 43 days for mRNA-1273.214 at time of interim analysis

moderna

Primary immunogenecity objectives for the Phase 2/3 study (P205)

The Day 29 testing sequence for the immunogenecity endpoints is the following:



Alpha=0.025

GMR: geometric mean titer ratio; SRR: seroresponse

moderna

Demographics and baseline characteristics were consistent between groups

Characteristics n (%)	mRNA-1273.214 (50 µg), N=437	mRNA-1273 (50 µg), N=377
Age at Screening (yr)		
Mean (range)	57.3 (20, 88)	57.5 (20, 96)
Age subgroup		
≥18 and <65 years	263 (60.2)	227 (60.2)
≥65 years	174 (39.8)	150 (39.8)
Gender		
Male	179 (41.0)	186 (49.3)
Female	258 (59.0)	191 (50.7)
Duration between second dose of mRNA-1273 in the primary series and the first booster of mRNA-1273 (months)		
Median	8.0	8.0
Q1, Q3	(7.4, 9.0)	(7.4, 8.5)
Duration between first booster injection of mRNA-1273 and the second booster (months)		
Median	4.5	4.4
Q1, Q3	(3.9, 4.9)	3.9, 4.9
SARS-CoV-2 infection Pre-booster		
Negative	340 (77.8)	267 (70.8)
Positive*	96 (22.0)	101 (26.8)
Missing	1 (0.2)	9 (2.4)

**SARS-CoV-2 testing was performed with polymerase chain reaction (PCR) and SARS-CoV-2 nucleocapsid antibody test. A positive test (either PCR or antibody test) was needed for the SARS-CoV-2 infection positive group.*

Solicited adverse reactions were consistent with prior doses

Solicited adverse reactions within 7 days of the dose



Solicited adverse reactions trended lower for mRNA-1273.214 compared to prior doses

Frequency and types of unsolicited adverse events were also comparable, with no vaccine-related serious events in the .214 group up to 28 days after the booster dose

Source trial: P301(primary, 100 µg dose 2); P201 (50 µg booster 1); P205 (50 µg booster 2)

moderna

Omicron neutralizing titers (PsVNT50)

Omicron neutralizing antibody titers (PsVNT50)



Omicron neutralizing titers **were significantly higher following bivalent (.214) booster** compared to prototype for all participants and both seronegative and baseline seropositive participants

moderna

Bivalent booster (.214) resulted in superior neutralizing GMT against Omicron

Only baseline seronegative participants

	mRNA-1273.214 50 µg (N=334)	**mRNA-1273** 50 µg (N=260)
Pre-booster GMT, 95% CI	298.13 (258.75, 343.49)	332.02 (282.05, 390.85)
Estimated GMTs (95% CI) at Day 29[a]	2479.89 (2264.47, 2715.80)	1421.24 (1282.98, 1574.41)
GMFR (95% CI) at Day 29, 95% CI	7.96 (7.18, 8.82)	4.44 (3.97, 4.96)
GMR (97.5% CI)[a]	**1.75** (1.49, 2.04)	
Seroresponse rate (95% CI) at Day 29[b]	333/333, 100 (98.9, 100)	256/258, 99.2 (97.2, 99.9)
Difference in seroresponse rates (97.5% CI)[c]	**1.5** (-1.1, 4.0)	

Primary endpoint for testing non-inferiority and superiority was seronegative participants

- **All primary and key secondary immunogenicity objectives were met**
  - mRNA-1273.214 **elicited superior neutralizing antibody response against Omicron**, compared to the prototype mRNA-1273 (50 µg) 28 days after the booster dose
  - mRNA-1273.214 **elicited a non-inferior seroresponse rate** compared to the prototype mRNA-1273 (50 µg) 28 days after the booster dose
- mRNA-1273.214 induced a **potent neutralizing antibody response against Omicron in all seronegative individuals** tested

[a] Based on ANCOVA modeling; the model includes adjustment for treatment group, pre-booster antibody titers, and age groups.
[b] Seroresponse at a participant level is defined as a change from below the LLOQ to equal or above 4 x lower limiting of quantification (LLOQ) if the participant's baseline is below the LLOQ, or at least a 4-fold rise if the baseline is equal to or above the LLOQ.
[c] 97.5% CI was calculated using a stratified Miettinen-Nurminen method and adjusting by age group. The SRR difference is a calculated common risk difference using inverse-variance stratum weights and the middle point of Miettinen-Nurminen confidence limits of each one of the stratum risk differences

moderna

Bivalent booster (.214) resulted in superior neutralizing GMT against Omicron

All participants

	mRNA-1273.214 50 µg (N=428)	**mRNA-1273** 50 µg (N=367)
Pre-booster GMT, 95% CI	432.05 (372.47, 501.17)	511.98 (433.39, 604.84)
Estimated GMTs (95% CI) at Day 29[a]	3232.52 (2951.83, 3539.89)	1815.14 (1650.05, 1996.74)
GMFR (95% CI) at Day 29, 95% CI	7.11 (6.48, 7.79)	3.78 (3.42, 4.17)
GMR (97.5% CI)[a]	**1.78** (1.56, 2.04)	
Seroresponse rate (95% CI) at Day 29[b]	380/380, 100 (99.0, 100)	340/342, 99.4 (97.9, 99.9)
Difference in seroresponse rates (97.5% CI)[c]	**1.2** (-1.3, 3.7)	

- Bivalent booster (.214) resulted in superior neutralizing GMT against Omicron compared to mRNA-1273 for all participants (includes both **seronegative participants** and **seropositive participants)**

[a] Based on ANCOVA modeling; the model includes adjustment for treatment group, prior SARS-CoV-2 infection, pre-booster antibody titers, and age groups.
[b] Seroresponse at a participant level is defined as a change from below the LLOQ to equal or above 4 x lower limiting of quantification (LLOQ) if the participant's baseline is below the LLOQ, or at least a 4-fold rise if the baseline is equal to or above the LLOQ.
[c] 97.5% CI was calculated using a stratified Miettinen-Nurminen method and adjusting by age group. The SRR difference is a calculated common risk difference using inverse-variance stratum weights and the middle point of Miettinen-Nurminen confidence limits of each one of the stratum risk differences

moderna

Bivalent booster (.214) meets non-inferior neutralizing GMT against ancestral SARS-CoV-2 (D614G)

	All participants		*Only baseline seronegative participants*	
	mRNA-1273.214 50 µg (N=428)	**mRNA-1273** 50 µg (N=367)	**mRNA-1273.214** 50 µg (N=334)	**mRNA-1273** 50 µg (N=260)
Pre-booster GMT, 95% CI	1266.74 (1120.19, 1432.47)	1521.00 (1352.77, 1710.15)	1603.35 (1420.26, 1810.05)	1944.78 (1725.35, 2192.12)
Estimated GMTs (95% CI) at Day 29[a]	6422.32 (5990.12, 6885.71)	5286.63 (4887.07, 5718.86)	6555.69 (6122.34, 7019.72)	5301.37 (4931.77, 5698.66)
GMFR (95% CI) at Day 29, 95% CI	4.72 (4.36, 5.11)	3.71 (3.42, 4.03)	4.13 (3.84, 4.44)	3.11 (2.88, 3.36)
GMR (97.5% CI)[a]	**1.22** (1.08, 1.37)		**1.24** (1.12, 1.37)	
Seroresponse rate (95% CI) at Day 29[b]	334/334, 100 (98.9, 100)	260/260, 100 (98.6, 100)	383/383, 100 (99.0, 100)	347/347, 100 (98.9, 100)
Difference in seroresponse rates (97.5% CI)[c]	**0**		**0**	

[a] Based on ANCOVA modeling; the model includes adjustment for treatment group, prior SARS-CoV-2 infection (only for the baseline seronegative participants), pre-booster antibody titers, and age groups.

[b] Seroresponse at a participant level is defined as a change from below the LLOQ to equal or above 4 x lower limiting of quantification (LLOQ) if the participant's baseline is below the LLOQ, or at least a 4-fold rise if the baseline is equal to or above the LLOQ.

[c] 97.5% CI was calculated using a stratified Miettinen-Nurminen method and adjusting by age group. The SRR difference is a calculated common risk difference using inverse-variance stratum weights and the middle point of Miettinen-Nurminen confidence limits of each one of the stratum risk differences

moderna

Conclusions

- The **mRNA-1273.214 50 µg booster dose was well-tolerated** and the safety and reactogenicity profile was similar to that of the prototype mRNA-1273 50 µg booster dose
- **All primary and key secondary immunogenicity objectives were met:**
  - mRNA-1273.214 (50 µg) **elicited a superior neutralizing antibody response against Omicron**, compared to the prototype mRNA-1273 (50 µg) 28 days after the booster dose
  - mRNA-1273.214 (50 µg) **elicited a non-inferior neutralizing antibody response against the ancestral SARS-CoV-2** compared to the prototype mRNA-1273 (50 µg) 28 days after the booster dose
- mRNA-1273.214 (50 µg) also induced a **potent neutralizing antibody response against Omicron in all individuals** regardless of prior SARS-CoV-2 infection status pre-booster

Our mission

To deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.

moderna